-+ 0.00%
-+ 0.00%
-+ 0.00%

Capricor to present 24-month HOPE-3 data on deramiocel in Duchenne muscular dystrophy at World Muscle Society congress

PUBT·09/17/2026 12:31:46
Listen to the news
Capricor to present 24-month HOPE-3 data on deramiocel in Duchenne muscular dystrophy at World Muscle Society congress
  • Capricor flagged new 24-month HOPE-3 results for deramiocel in advanced Duchenne muscular dystrophy, slated for late-breaking release at WMS 2026.
  • The data are positioned to support both muscle function and cardiac benefit, extending previously disclosed 12-month findings.
  • Analyses include delayed-start and natural-history comparisons, submitted in a major amendment to the deramiocel BLA.
  • WMS 2026 runs Sept. 29 to Oct. 3 in Hiroshima; an oral clinical-trial update is scheduled for Oct. 3.
  • The FDA PDUFA target action date for the deramiocel BLA is Nov. 22, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170830PRIMZONEFULLFEED9828829) on September 17, 2026, and is solely responsible for the information contained therein.